Sachetta’s Enanta Pharmaceuticals ENTA Stock Holding History

Sachetta’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$1.2K	–	1052
2025 Q3	$1.2K	Hold	100	–	–	﹤0.01%	938
2025 Q2	$756	Hold	100	–	–	﹤0.01%	1003
2025 Q1	$552	Hold	100	–	–	﹤0.01%	1026
2024 Q4	$575	Hold	100	–	–	﹤0.01%	1077
2024 Q3	$1.04K	Buy	+100	New	+$1.31K	﹤0.01%	1024

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sachetta's ENTA Position: Q4 2025 in Review

Sachetta sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 100 shares — an estimated $1.2K sold.

Sachetta first reported a position in ENTA in Q3 2024 and held it in 5 quarters. The position peaked at $1.2K in Q3 2025. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

Sachetta reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sachetta sold 100 Enanta Pharmaceuticals shares in Q4 2025, an estimated $1.2K.
Sachetta first reported a position in Enanta Pharmaceuticals in Q3 2024 and held it in 5 quarters.
Sachetta's Enanta Pharmaceuticals position peaked at $1.2K in Q3 2025.
131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Sachetta's 13F filing for Q4 2025, filed 2 Feb 2026.